Matulonis and colleagues initially reported the combination between BKM120, a nonselective PI3K inhibitor, and olaparib in patients with breast and ovarian cancers was possible with dose attenuation of the BKM120 in 2017 as we were initiating this trial.40 The gene discussed is PIK3CA; the disease is ovarian cancer.